

TECHNICAL REPORT

Reduced Cytotoxicity by Repetitive mRNA Transfection in Differentiated Neurons

Seung Hwan Ko^{1,*}, Jin Sun Kang^{1,*}, Sang-Mi Kim², Eun-Hye Lee^{3,4}, Chang-Hwan Park^{1,2,5}

¹*Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea*

²*Hanyang Biomedical Research Institute, Hanyang University, Seoul, Korea*

³*Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA*

⁴*Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA*

⁵*Department of Microbiology, College of Medicine, Hanyang University, Seoul, Korea*

Background and Objectives: mRNA-based protein expression technology has been used to express functional proteins. We have previously generated dopamine neurons from rat-embryo derived neural precursor cells (NPCs) through repeated transfection of synthetic transcription factor mRNA encoding dopamine-inducible genes. However, NPCs began to die approximately 10 d post-transfection. In this study, we examined a long-term transfection protocol that did not affect cell viability.

Methods and Results: Experiments were performed in eight groups sorted according to the start date of mRNA transfection. mRNA was transfected into NPCs daily for 21 d and live cell images of each group were recorded. NPCs which were differentiated for more than five days showed sustained gene expression and appreciable viability despite daily mRNA transfection for 21 d.

Conclusions: Repeated mRNA transfection requires cells with a sufficient differentiation period.

Keywords: Delayed initiation, mRNA transfection, Neuronal differentiation, Neuron survival

Introduction

Various techniques for exogenous protein expression have been widely used in both research and medicine. DNA-based gene expression using viral and non-viral vec-

tors is most commonly used to express functional proteins in cells (1). However, DNA-based approaches have several drawbacks, including integration into the host genome and increased immunogenicity.

Recently, synthetic mRNA-based protein expression has emerged as an attractive alternative for DNA-based gene expression (2). The strategy is based on non-viral technology and has an advantage in terms of safety because mRNA itself does not enter the nucleus or integrate into the host genome (3, 4). In addition, mRNA-mediated protein expression works in both mitotic and post-mitotic cells, in contrast to DNA-mediated gene expression (5). Furthermore, delivery of multiple mRNAs in one step together makes it possible to express multiple genes stoichiometrically (6). Despite these advantages over DNA-based expression, the technique still has concerns with respect to stability and immunogenicity given that mRNA is prone to rapid degradation within the cytoplasm due to

Received: July 19, 2022, Revised: November 1, 2022,
Accepted: November 7, 2022, Published online: December 31, 2022
Correspondence to Chang-Hwan Park

Graduate School of Biomedical Science & Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea
Tel: +82-2-2220-0646, Fax: +82-2-2220-2422
E-mail: chshpark@hanyang.ac.kr

*These authors contributed equally to this work.

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2022 by the Korean Society for Stem Cell Research

its unstable structure, and introduction of mRNA into cells can induce the interferon pathway.

We have previously successfully generated dopaminergic (DA) neurons from neural precursor cells (NPCs) by transfection of mRNAs encoding the *Nurr1* and *FoxA2* genes (7). However, the mRNA-based differentiation of DA neurons requires daily transfection of dopamine-inducible mRNAs because of the short half-life of mRNA. Repeated mRNA transfection was essential for the stable expression of NURR1 and FOXA2 proteins. Unfortunately, undesirable cytotoxicity in NPCs occurs during daily and repeated transfections of mRNA, suggesting that transfecting large amounts of mRNA resulted in cytotoxicity (7).

In this study, we examined whether temporal control of mRNA transfection affects the cytotoxicity of NPCs. Pre- or post-differentiated NPCs were subjected to daily mRNA transfection for 21 d. We found that the initial transfection of mRNA after 5 d of differentiation showed notably low cytotoxicity in NPCs. Together, these data suggest that cytotoxicity can be reduced by temporal control of mRNA transfection.

Materials and Methods

Rat NPC isolation and culture

The animals were housed and treated according to the Institutional Animal Care and Use Committee (IACUC 2021-0065) guidelines of Hanyang University, Korea. Rat NPCs were obtained from the brain cortical tissues of Sprague-Dawley rat embryos (embryonic day 14) (Daehan Biolink, Seoul, Korea). Rat NPCs were cultured in dishes coated with 15 μ g/ml poly-L-ornithine (PLO; Sigma-Aldrich, St Louis, MO, USA) and 1 μ g/ml fibronectin (FN; Sigma-Aldrich) and incubated at 37°C and 5% CO₂. To enable expansion of rat NPCs, the cells were cultured in a N2 medium supplemented with 20 ng/ml basic fibroblast growth factor (bFGF, R&D Systems, Minneapolis, MN, USA). For neuronal differentiation, the cells were cultured in a N2 medium supplemented with 0.2 mM ascorbic acid (Sigma-Aldrich), 20 ng/ml brain-derived neurotrophic factor (R&D Systems), 20 ng/ml glial cell-derived neurotrophic factor (R&D Systems), and 250 μ g/ml dibutyryl-cAMP (Sigma-Aldrich).

Plasmid construction

The pcDNA/UTR55A vector for mRNA synthesis was prepared by modifying the pcDNA3.1(+) plasmid (Invitrogen, Carlsbad, CA, USA). Several restriction enzyme sites (896~930 and 980~992 bp) of pcDNA3.1(+) were replaced with multiple cloning sites (*NheI*, *BamHI*, *NotI*,

and *XbaI*). Oligonucleotide sequences of the 5'-untranslated region (UTR) forward, 5'-UTR reverse, 3'-UTR forward, 3'-UTR reverse, 55pA forward, and 55pA reverse (Integrated DNA Technologies, Coralville, IA, USA) were annealed and inserted into the pcDNA3.1(+). Enhanced green fluorescent protein gene (*EGFP*) was inserted between the 5'- and 3'-UTR of pcDNA/UTR55A as a reporter of successful transfection and gene expression.

Preparation of EGFP mRNA

RNA was synthesized as previously described (7). The construct encoding EGFP mRNA was linearized using *EcoRV* (Takara Bio, Shiga, Japan). RNA was prepared using the MEGAscript T7 kit (Ambion, Austin, TX, USA), with the digested construct as a template. To prepare the final construct, we applied 5' capping and poly (A) tailing to the RNA using the ScriptCap m7G capping system, 2'-O-methyltransferase, and poly (A) polymerase kit (CELLS-CRIPT, Madison, WI, USA). Finally, mRNA was precipitated with 2.5 M ammonium acetate (Ambion) and dissolved in an RNA Storage Solution (Ambion). EGFP mRNA was stored at -70°C at a concentration of 1 mg/ml (Fig. 1).

mRNA transfection

mRNA transfection was performed as previously described (7). One day before transfection, NPCs (50,000 cells/Ø12 mm) were seeded onto glass slides in 24-well plates coated with PLO/FN, and incubated in an expansion medium. Synthetic mRNA and transfection reagent Lipofectamine 2000 (Invitrogen) were separately diluted in an Opti-Minimal Essential Medium (Opti-MEM; Invitrogen) and incubated for five minutes at room temperature, after which the two Opti-MEM samples were mixed and incubated at room temperature for 20 min. The 24-well plates seeded with mouse NPCs were washed with Opti-MEM, and fresh Opti-MEM was added to the wells. The mRNA-lipofectamine mixture was then added to the wells. After three hours, the solutions in the transfected wells were replaced with expansion medium.

Cell viability assay

The NPCs were seeded into a PLO/FN-coated 24-well plate and divided into several groups. Each group consisted of three wells and was classified according to transfection initiation day. Live cells were recorded daily using a Nikon camera (D5600) and microscope (Eclipse Ta2-FL) for 21 d, and Kaplan-Meier survival curves were generated.




Fig. 1. Preparation of mRNA encoding *EGFP*. Prepared plasmid DNA of *EGFP* mRNA was linearized using the restriction enzyme *EcoRV*. Linearized DNA was used as a template for *in vitro* transcription. To prepare the final mRNA, a 5'-cap and poly(A) tail were added to the *in vitro*-transcribed RNA.

Results

The mRNA encoding *EGFP* was used to monitor gene expression (Fig. 1). NPCs harvested from rat embryonic brains on embryonic day 14 were expanded in the N2 medium supplemented with bFGF for 2 d. After 2 d, the NPCs were subjected to differentiation into neuronal cells in the N2 medium without bFGF. The cultured cells were divided into eight groups, as indicated in Table 1, and subjected to daily transfection for 21 d (Fig. 2). The *EGFP* expression and cell viability were evaluated daily. Cells from groups 1 to 6 showed high lethality after the 10th transfection (Fig. 3, Supplementary Fig. S1~S3). However, significant cytotoxicity was not observed in groups 7 and 8 even after the 21st transfection, suggesting that the start of mRNA transfection at the late differentiation period can reduce cytotoxicity due to repetitive mRNA loads (Fig. 3B).

Discussion

Genetic diseases, which are mostly incurable, include all illnesses caused by abnormal changes in a patient's genes. Gene therapy replaces a mutated gene or adds a new gene to either produce a therapeutic effect, or to treat the disease. Gene therapy has been demonstrated to be useful for treating genetic diseases and cancers through fusion of genes with therapeutic effects (8-10).

Gene transfer using viral vectors, including lentiviruses

Table 1. Group classification

Group number	Time point of mRNA transfection initiation
Group 1 [Exp. D1]	1 d after cell seeding (expansion day 1)
Group 2 [Exp. D2]	2 d after cell seeding (expansion day 2)
Group 3 [Diff. D1]	3 d after cell seeding (expansion 2 d+differentiation day 1)
Group 4 [Diff. D2]	4 d after cell seeding (expansion 2 d+differentiation day 2)
Group 5 [Diff. D3]	5 d after cell seeding (expansion 2 d+differentiation day 3)
Group 6 [Diff. D4]	6 d after cell seeding (expansion 2 d+differentiation day 4)
Group 7 [Diff. D5]	7 d after cell seeding (expansion 2 d+differentiation day 5)
Group 8 [Diff. D7]	9 d after cell seeding (expansion 2 d+differentiation day 7)

and adeno-associated viruses, has effective gene expression capability (11-13). However, target genes encoded by viral vectors have the potential to be randomly integrated into the recipient's chromosomes because of their viral nature. Considering these safety issues, we chose mRNA as the non-viral vector for gene delivery. A gene transfer system using mRNA is safer than using viral vectors (4, 14), but the system has some disadvantages, such as low gene transfer efficiency and rapid degradation of mRNA vectors (15).

To prevent the rapid degradation of mRNA within 1~2 d,




Fig. 2. Daily mRNA transfection experiment 1. The transfection start date varied according to the initial differentiation period. The neural precursor cells from each group were transfected with *EGFP* mRNA for 21 d.




Fig. 3. Cell viability and live cell images following repeated mRNA transfection. Synthetic *EGFP* mRNA was transfected each day into the rat neural precursor cells. (A) Viability graph was prepared by quantifying the wells that died out of three wells for each group during daily mRNA transfection, and (B) *EGFP*-expressing live cells of two groups (groups 1 and 8) were recorded. The scale bar represents 100 μ m.

we performed daily transfection of mRNA encoding a specific gene to induce long-term expression. Using this method, the NPCs were converted into dopaminergic cells. When mRNA transfection was performed daily, early transfected NPCs did not survive in the long term, whereas NPCs differentiated for more than seven days maintained their gene expression under normal conditions for 21 d with daily transfection (7).

In the present study, we investigated the duration to which NPCs must be differentiated to enable the long-term expression of genes without affecting cell conditions during daily mRNA transfection. An mRNA vector encoding *EGFP* was synthesized and used for the convenient observation of gene expression. The transfection start date varied according to the initial differentiation period, with 21 transfections conducted daily in triplicate. NPCs differentiated for fewer than five days exhibited cell death after the 10th transfection. NPCs differentiated for more than six days remained stable throughout all 21 transfections, with strong long-term EGFP expression.

Although further confirmation from different cell types is required, this phenomenon may be a stabilizing effect according to neuron formation and differentiation of astrocytes from NPCs. NPCs and neurons are vulnerable to external stimuli, but their stability increases in the presence of astrocytes and supporting cells (16). When NPCs are cultured in neuron-conditioned medium (NCM), the cells differentiate into TUJ1-positive neurons and GFAP-positive astrocytes (17, 18). In our experiment, an increase in the number of astrocytes was also observed during NPC culture with NCM (Supplementary Fig. S3).

Daily mRNA transfection is considered as an unbearable level of damage in these undifferentiated NPCs, possibly resulting in cell death. When NPCs are subjected to a sufficient differentiation period, the cells may be maintained in stable conditions with astrocyte support.

Our study provides a foundation for the further analysis of daily mRNA transfection to achieve continuous gene expression for gene therapy.

Acknowledgments

This work was supported by the Individual Basic Science and Engineering Research Program (2019R1A2C2005681) of the National Research Foundation of the Ministry of Science and ICT in Korea.

Potential Conflict of Interest

The authors have no conflicting financial interest.

Supplementary Materials

Supplementary data including three figures can be found with this article online at <https://doi.org/10.15283/ijsc22125>.

References

1. Sung YK, Kim SW. Recent advances in the development of gene delivery systems. *Biomater Res* 2019;23:8
2. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. *Nat Rev Drug Discov* 2014;13:759-780
3. McLenachan S, Zhang D, Palomo AB, Edel MJ, Chen FK. mRNA transfection of mouse and human neural stem cell cultures. *PLoS One* 2013;8:e83596
4. Schlaeger TM, Daheron L, Brickler TR, Entwistle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, Brookes E, Cherry AB, Demirbas D, Tsankov AM, Zon LI, Rubin LL, Feinberg AP, Meissner A, Cowan CA, Daley GQ. A comparison of non-integrating reprogramming methods. *Nat Biotechnol* 2015;33:58-63
5. Yamamoto A, Kormann M, Rosenecker J, Rudolph C. Current prospects for mRNA gene delivery. *Eur J Pharm Biopharm* 2009;71:484-489
6. Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. *Nat Protoc* 2013; 8:568-582
7. Kim SM, Lim MS, Lee EH, Jung SJ, Chung HY, Kim CH, Park CH. Efficient generation of dopamine neurons by synthetic transcription factor mRNAs. *Mol Ther* 2017;25: 2028-2037
8. Bulaklak K, Gersbach CA. The once and future gene therapy. *Nat Commun* 2020;11:5820
9. Giamas G, Gagliano T. Cancer gene therapy 2020: highlights from a challenging year. *Cancer Gene Ther* 2022;29: 1-3
10. Papanikolaou E, Bosio A. The promise and the hope of gene therapy. *Front Genome Ed* 2021;3:618346
11. Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. *Signal Transduct Target Ther* 2021;6:53
12. Lundstrom K. Viral vectors in gene therapy. *Diseases* 2018; 6:42
13. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. *Nat Rev Drug Discov* 2019;18:358-378
14. Huang CL, Leblond AL, Turner EC, Kumar AH, Martin K, Whelan D, O'Sullivan DM, Caplice NM. Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction. *Mol Pharm* 2015;12:991-996
15. Zhou X, Hao R, Chen C, Su Z, Zhao L, Luo Z, Xie W. Rapid delivery of nanobodies/VHHs into living cells via ex-

- pressing in vitro-transcribed mRNA. *Mol Ther Methods Clin Dev* 2020;17:401-408
16. Wang XF, Cynader MS. Effects of astrocytes on neuronal attachment and survival shown in a serum-free co-culture system. *Brain Res Brain Res Protoc* 1999;4:209-216
17. Chang MY, Son H, Lee YS, Lee SH. Neurons and astrocytes secrete factors that cause stem cells to differentiate into neurons and astrocytes, respectively. *Mol Cell Neurosci* 2003;23:414-426
18. Wang FW, Hao HB, Zhao SD, Zhang YM, Liu Q, Liu HJ, Liu SM, Yuan QH, Bing LJ, Ling EA, Hao AJ. Roles of activated astrocyte in neural stem cell proliferation and differentiation. *Stem Cell Res* 2011;7:41-53